Company intelligence / Profile preview
Sarcomatrix Therapeutics
Reno, Nevada, United States of Americasarcomatrix.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Sarcomatrix Therapeutics is a pre-clinical stage biotech developing first-in-class oral small molecule drugs that enhance α7β1 integrin activity to promote muscle regeneration. Their lead candidate S‑969 has shown promise in stimulating satellite cell activation and myofiber fusion in preclinical models. The company is leveraging its proprietary screening platform and advanced research in extracellular matrix biology and integrin signaling to address severe muscle-wasting diseases such as muscular dystrophies, with future plans for cachexia and sarcopenia.
- Therapeutic areas
- OncologyMetabolic DisordersNeurology
- Modalities
- Small moleculeProtein
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Strategic collaboration announced March 2025 with an undisclosed partner for development of muscular dystrophy therapeutics
Beyond the preview
Go deeper on Sarcomatrix Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sarcomatrix Therapeutics.